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The relation of clinical and electrophysiologic variables
to outcome was evaluated in 121 patients treated with
amiodarone for sustained ventricular tachyarrhythmias.
Electrophysiologic study was performed in all patients
a mean of 14 days after beginning amiodarone therapy.
Forty-six patients who were given oral amiodarone ther-
apy experienced arrhythmia recurrence. Multivariate
analysis was performed using 16 clinical and electro-
physiologic variables to determine which factors were
associated with 1)arrhythmia recurrence and 2) a poorly
tolerated arrhythmia recurrence (that is, cardiac arrest
or sudden cardiac death) during oral amiodarone ther-
apy. No variable predicted arrhythmia recurrence. Five
variables correlated significantly with a poorly tolerated
arrhythmia recurrence. Hemodynamic stability of the
arrhythmia induced on electrophysiologic testing during
Amiodarone has been widely used for the treatment of ven-
tricular arrhythmias. We (1) and others (2) have found that
most patients continue to have sustained arrhythmias in-
ducible at electrophysiologic study during short- and long-
term amiodarone therapy. It is controversial whether in-
ducibility of arrhythmia during amiodarone therapy corre-
lates with drug success (1-8) . The selection of patients who
are most suitable for amiodarone treatment is thus difficult.
We undertook this analysis in an attempt to determine
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amiodarone therapy had the best predictive value (p <
0.001). Younger age, lower ejection fraction, a poorly
tolerated rhythm at clinical presentation and absence of
left ventricular aneurysm were also associated with a
poorly tolerated arrhythmia recurrence.
Only 3 of 57 patients who had a well tolerated ar-
rhythmia induced on electrophysiologic testing during
amiodarone therapy had recurrence of a poorly tolerated
arrhythmia versus 19 of 47 who had hemodynamicalJy
unstable arrhythmias induced during amiodarone ther-
apy (p < 0.001). Thus, electrophysiologic testing during
amiodarone therapy appears useful in identifying pa-
tients who are prone to have catastrophic arrhythmia
recurrences and could allow for the institution of ad-
ditional or alternative modes of therapy,
(J Am Coli Cardiol1987;lO:90-6)
whether the hemodynamic consequences of the arrhythmia
induced during electrophysiologic study during amiodarone
therapy or other clinical and electrophysiologic factors could
identify those patients most likely to experience life-threat-
ening symptoms with recurrence of ventricular tachycardia
or fibrillation . The ability to identify patients at high risk
for recurrence of an arrhythmia capable of producing life-
threatening symptoms or sudden death might allow for ad-
j unctive or alternative therapy , or both , to be instituted
(9-12).
Methods
Study patients. The study group consisted of 121 pa-
tients who had I) spontaneous sustained ventricular tachy-
card ia or cardiac arrest ; and 2) electrophysiologic studies
after 10 to 21 days of amiodarone therapy . Characteristics
of the group are shown in Table I .
Definitions. Rhythms induced at electrophysiologic study
and spontaneous rhythms were defined as tolerated or not
tolerated by the following criteria:
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Table 1. Characteristics of the \2\ Study Patients
Variable Mean SD Range
Age (yr) 59 II 22 to 78
Spontaneous 4.1 4.7 I to 20
arrhythmia
episodes (no.)
Failed drugs (no.) 2.7 1.8 I to 12
Ejection 35 17 9 to 80
fraction (%)
No. Pk
Sex
Male 98 81
Female 23 19
Aneurysm (no.) 65 54
Heart disease
Coronary artery disease 102 85
Idiopathic cardiomyopathy 14 12
Other* 5
*Two patients had mitralvalve prolapse. two had arrhythmogenic right
ventricular dysplasia and one had tetralogy of Fallot.
Spontaneous rhythm . Nontolerated, hemodynamically
unstable , Patients who had at least one single episode of
arrhythmia that was hemodynamically unstable leading to
syncope or cardiac arrest were classified as having a he-
modynamically unstable arrhythmia even if other episodes
of hemodynamically tolerated sustained ventricular tachy-
cardia were present. Tolerated. Documented sustained ven-
tricular tachycardia not associated with either syncope or
cardiac arrest.
Indu ced rhythm. Nontolerated, hemodynamically unsta-
ble . Ventricular fibrillation or ventricular tachycardia as-
sociated with loss of consciousness or presyncope. Toler -
ated . Sustained ventricular tachycardia not associated with
loss of consciousness or symptomatic hypotension.
Recurrent arrhythmias . Documented episodes of sus-
tained ventricular tachycardia, cardiac arrest or syncope
(without any other identifiable cause) that occurred after at
least 2 weeks of oral therapy with amiodarone.
Sustained ventricular tachycardia . Ventricular tachy-
cardia that lasted > 30 seconds or was associated with hemo-
dynamic collapse requiring cardioversion in < 30 seconds.
Sudden cardiac death . Death occurring within 12 hour
of the onset of symptoms or during sleep in a patient free
of symptoms during the preceding 24 hours and in whom
no other cause of death was discernible.
Electrophysiologic study protocol. Baseline studies were
performed with patients in the fasting and nonsedated state
after informed consent was obtained. Antiarrhythmic agents
were discontinued 24 to 48 hours before the control study.
The protocol and equipment used for programmed stimu-
lation have been described previously in detail (13). Three
or four electrode catheters were inserted percutaneously or
by venous cutdown and positioned in the heart under flu-
oroscopic guidance. Routinely, quadripolar catheters were
positioned in the high right atrium. right ventricular apex
and outflow tract and a tripolar catheter was used at the
atrioventricular (AV) junction for His bundle recording.
Electrical stimulation was performed with a specially
designed digital stimulator and an optically isolated constant
current source (Bloom Associates, Ltd.). The stimuli were
rectangular pulses I ms in duration delivered at twice dia-
stolic threshold. Intracardiac recordings were filtered at 30
to 500 Hz and recorded simultaneously with three electro-
cardiographic (ECG) leads (I, aVF and Vd .
Stimulation techniques [or init iating ventricular arrhyth -
mias during control and subsequent studies included the
introduction of one to three ventricular extrastimuli during
sinus rhythm or ventricular pacing at multiple cycle lengths
(routinely 600 and 400 rns) from the right ventricular apex
and outflow tract. Rapid ventricular pacing at cycle lengths
of 400 to 250 ms was also performed for 10 to 30 seconds.
End points of theelectrophysiologic study were reproducible
induction of sustained ventricular tachycardia, induction of
ventricular fibrillation or completion of the study protocol.
Patients had electrophysiologic studies performed in the
control state and after 10 to 21 days (mean 14) after begin-
ning amiodarone therapy.
Drug therapy. Amiodarone therapy was routinely in-
stituted at a dose of 1,400 rug/day for I week (a total of
9.5 g). After I week. maintenance therapy was begun and
consisted of 400 rug/day in 112 of 121 patients. Seven
patients received 600 mg and two patients 800 mg daily.
Twenty-seven or our pat ients were treated with a type I
antiarrhythmic agent durin g the fo llow-up period. In some
patients this was done in an attempt to suppress arrhythmia
inducibility before it became clear that most patients con-
tinue to have inducible ventricular tachycardia during amio-
darone therapy despite apparent treatment success. Several
other patients were part of a separate protocol to examine
the effects of the addition of type I antiarrhythmic agents
to amiodarone in patients with rapid tachycardias.
Statistical analysis. Multivariate analysis was per-
formed using the Cox stepwise proportional hazards linear
model. Variables used in the multivariate analysis are listed
in Table 2. Variables such as ejection fraction and age were
used as continuous variables in the multivariate analysis
because dichotomizing them decreased the predictive value
of the model. Because of significant covariance between
arrhythmia tolerance and arrhythmia cycle length (at pre-
sentation. baseline electrophysiologic study and electro-
physiologic study during amiodarone therapy) these vari-
ables were not included in statistical analysis at the same
time. but sequential analysis was performed using each group
of variables. Multivariate analysis was used in an attempt
to identify factors associated with two outcome variables.
We searched for factors associated with the presence or
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Table 2. Variables Used in Multivariate Analysis
Age
Sex
Presence of coronary artery disease
Ejection fraction
Presence of left ventricular aneurysm
Arrhythmiaepisodes
Failed drugs
Therapy with type I agents
Side effects
Presenting arrhythmiacycle length
Tolerance of presenting arrhythmia
Cycle length of induced arrhythmia without drug therapy
Tolerance of induced arrhythmia without drug therapy
Cycle length of induced arrhythmiaduring amiodarone therapy
Tolerance of induced arrhythmiaduring amiodarone therapy
Arrhythmia inducibility during amiodarone therapy
absence of arrhythmia recurrence during amiodarone ther-
apy and in a separate analysis attempted to determine those
factors that would identify whether or not an arrhythmia
recurrence would be tolerated. We specifically wanted to
identify those factors that might be associated with occur-
rence of cardiac death or syncope during drug therapy. In
addition, because multivariate analysis requires patient in-
formation for each variable, the inducibility of a ventricular
arrhythmia could not be analyzed simultaneously in an anal-
ysis that included the hemodynamic stability of rhythm in-
duced at electrophysiologic testing. Thus, a third multivar-
iate analysis was performed in which "tolerance" variables
were not used but inducibility or noninducibility of ven-
tricular arrhythmia was included. A probability (p) value of
<0.1 was taken as significant in the Cox proportional haz-
ards model. Life table analysis was performed using the
Kaplan-Meier life table analysis technique. All values are
expressed as the mean ± SD. Univariate analysis was per-
formed using chi-square or Fisher's exact test when appro-
priate.
Results
Clinical presentation. Forty-nine of 121 patients had a
history of hemodynamically stable ventricular tachycardia
and were classified as having tolerated spontaneous arrhyth-
mias. Seventy-two patients had a history of hemodynami-
cally unstable presenting arrhythmias. Of these, 19 had syn-
cope with rapid ventricular tachycardia and 53 patients had
a cardiac arrest. Twenty-three of these 53 patients also had
distinct episodes of hemodynamically well tolerated ven-
tricular tachycardia. Thus 30 (25%) of the 121 patients
presented with cardiac arrest alone and the remainder had
at least one episode of ventricular tachycardia.
Baseline electrophysiologic study. Of the 121 patients,
110 underwent baseline electrophysiologic study while tak-
ing no antiarrhythmic agents. Ninety-eight patients (89%)
had inducible sustained uniform ventricular tachycardia, 10
patients (9%) had inducible sustained polymorphic ventric-
ular tachycardia or ventricular fibrillation and 2 did not have
arrhythmias induced (one had 8 seconds of inducible non-
sustained polymorphic ventricular tachycardia). Twenty (18%)
had ventricular arrhythmia induced with one extrastimulus,
64 (59%) with two extrastimuli, 23 (21%) with three ex-
trastimuli and one with rapid pacing. The mean cycle length
of induced sustained uniform ventricular tachycardia was
262 ± 60 ms. At baseline electrophysiologic study, a he-
modynamically unstable tachycardia was induced in 76 pa-
tients (70%) and a tolerated tachycardia was induced in 32
patients (30%).
Electrophysiologic study during amiodarone therapy.
During electrophysiologic study during amiodarone therapy,
16 patients did not have arrhythmias induced (1 of them
had noninducible arrhythmia at baseline), 2 had ventricular
fibrillation induced and 103 patients had uniform sustained
ventricular tachycardia induced. Forty-seven patients (46%)
had hemodynamically stable ventricular tachycardia, and 58
patients (56%) had a hemodynamically unstable ventricular
tachycardia induced. Twenty-nine patients (28%) had sus-
tained ventricular arrhythmias induced with one extrasti-
mulus, 54 (52%) with two extrastimuli and 22 (21%) with
three extrastimuli. In 46 patients, the number of extrastimuli
required to initiate the tachycardia was the same as that in
the baseline study. Of the remaining patients, 36 required
fewer extrastimuli than in the baseline state, 22 required
more extrastimuli and 1 patient did not have a sustained
ventricular tachycardia induced in the baseline state.
Eighty-nine patients had sustained ventricular tachycar-
dia induced at both baseline and follow-up studies. In 69
of these 89 patients in whom a tachycardia of a configuration
similar to that at baseline electrophysiologic study was in-
duced, the mean cycle length of ventricular tachycardia
induced at follow-up study was 314 ± 71 ms (p < 0.05
versus control). In 20 patients in whom ventricular tachy-
cardia of multiple configurations and rates was induced, the
tolerance of the tachycardia with the shortest cycle length
induced was used for classifying patients. In the patients
with a hemodynamically unstable tachycardia, the mean
cycle length was 268 versus 351 ms in those patients with
a tolerated tachycardia (p < 0.001). There was, however,
some overlap between the two groups (Fig. 1).
Outcome. Seventy-four patients remain free of arrhyth-
mia recurrence after a mean follow-up interval of 27 months
(range 1 to 67) (Group 1). In 23 of these patients, amio-
darone was discontinued: in 14 because of side effects, in
6 because the patients elected to undergo surgical therapy
for arrhythmia rather than continue drug therapy and in 3
because patients elected to discontinue the drug on their
own. In 13 of the 23 patients in whom amiodarone was
discontinued, the duration of arrhythmia-free follow-up was
<6 months; however, because the Cox logistic regression
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Figure 1. Relation of cycle length to clinical tolerance of ven-
tricular tachycardia induced at electrophysiologic study during
amiodarone therapy. Those patients with hemodynamically unsta-
ble tachycardia had a mean cycle length of 264 versus 350 ms in
those patients with a tachycardia tolerated hemodynamically (p <
0.05). There was, however, significant overlap between the groups.
VTCL = cycle length of ventricular tachycardia induced at elec-
trophysiologic study; EPS RHYTHM = rhythm induced at elec-
trophysiologic study; TOL = tolerated hemodynamically; N-TOL
= hemodynamically unstable.
Table 3. Results of Multivariate Analysis: Correlation With
Poorly Tolerated Recurrence
0.084
0.016
0.015
0.049
O.OOj
p Value
Nontolerated presenting arrhythmia
Nontolerated rhythm induced during amiodarone
therapy
Absence of aneurysm
Lower ejection fraction
Younger age
darone therapy. Five of these patients had arrhythmia re-
currence. The inducibility of ventricular arrhythmia at elec-
trophysiologic study did not correlate with arrhythmia
recurrence or recurrence of poorly tolerated arrhythmia in
either univariate or multivariate analysis. None of the vari-
ables tested were significantly correlated with arrhythmia
recurrence. Multivariate analysis was then repeated to ex-
amine correlates of a poorly tolerated recurrence. In this
analysis, Group I (those patients with no arrhythmia re-
currence) and Group 2 (those with tolerated recurrence) were
evaluated against Group 3 (those with nontolerated arrhyth-
mia recurrence). Five variables had an independent predic-
tive value for poorly tolerated arrhythmia recurrence (Table
3). The most powerful correlates were tolerance of arrhyth-
mia induced at electrophysiologic testing during amiodarone
Variable
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Figure 2. Survival curves showing the percent of patients free
from sudden cardiac death in those patients with well (dashed
line) andpoorly (solidline) tolerated arrhythmias induced at elec-
trophysiologic study during amiodarone therapy. Data from the93
patients used in the multivariate analysis comparing these two
groups are shown. The probability value was <0.001 for this
comparison with both univariate and multivariate analysis. The
number of patients remaining in each group at any given time is
shown in parentheses.
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analysis corrects for differences in follow-up time, these
patients remained in the analysis. Forty-six patients expe-
rienced documented (41 patients) or presumed (syncope, 5
patients) arrhythmia recurrence after 2 weeks to 39 months
of therapy (mean 8.6 months). All five patients who had
syncope during amiodarone therapy presented initially with
loss of consciousness or cardiac arrest. Twenty patients had
recurrence of tolerated arrhythmia (Group 2) and 26 of non-
tolerated arrhythmia (Group 3). Seventeen patients died sud-
denly, 5 had syncope and 4 had ventricular fibrillation doc-
umented during successful resuscitation from cardiac arrest.
Of the 14 patients with side effects requiring discontin-
uation of amiodarone therapy, 7 had pulmonary toxicity, 2
had neurotoxicity, 2 had intolerable photosensitivity and I
each had anorexia, psoriasis and hepatic toxicity. Twenty-
three patients died of causes other than sudden cardiac death.
Although II of these patients died of progressive and re-
fractory congestive heart failure, it is impossible to say what
role if any amiodarone played in their death because all 11
patients had a severely depressed ejection fraction before
beginning drug therapy.
Variables associated with outcome during amioda-
roue therapy. Of note, in only 14(13%) of the 108 patients
in the study group who had inducible arrhythmia at baseline
study did the arrhythmia become noninducible during amio-
90
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Arrhythmia Recurrence
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Variable
Base-hemodynamically unstable
Amio-hemodynarnically unstable
Aneurysm present
Ejection fraction «35%)
Age « 55 years)
Nontoleratedt
21 of 26
19 of 22
13 of 25
17 of 25
8 of 26
None or
Tolerated
50 of 94
28 of 82
49 of 91
50 of 92
26 of 94
p Value
p < 0.02
p < 0.001
NS
NS
NS
*No other variables were significant in univariate analysis. t Cardiac arrest or syncope as a recurrent
arrhythmia. Arnie-hemodynamically unstable = hemodynamically unstable arrhythmia induced at electro-
physiologic study on amiodarone; Base-hemodynamically unstable = hemodynamically unstable arrhythmia
induced at baseline electrophysiologic study.
therapy (p = 0.001), younger age (p = 0.015) and lower
ejection fraction (p = 0.016) . Tolerance of arrhythmia in-
duced at electrophysiologic testing during amiodarone ther-
apy alone provided differentiation of patients into high and
low risk groups for a poorly tolerated arrhythmia recurrence
through the follow-up period (Fig. 2). The r value for this
variable alone was 0.245 , whereas it was 0.370 for the
whole model. The results of univariate analysis for those
variables (with age and ejection fraction dichotomized) are
shown in Table 4. The cycle length of induced ventricular
tachycardia in the absence of antiarrhythmic agents was 308
ms in patients who were subsequently treated with arnio-
darone plus a type I agent versus 317 ms in those who were
treated with amiodarone alone (p = NS). The use of a type
I agent in this patient group was not predictive of either
outcome variable.
Discussion
We studied a group of 121 patients with sustained ven-
tricular tachyarrhythmias and found that 57% were effec-
tively treated with amiodarone during a mean arrhythmia-
free follow-up period of 27 months. Arrhythmia recurrence
and sudden death rate after 1 year of amiodarone therapy
were 24 and 14%, respectively. Short- and long-term suc-
cess rates during amiodarone therapy in prior studies have
ranged from 42 to 88% in similar patient groups (2,3,5,6).
Thus, although amiodarone is useful in many patients with
drug-refractory ventricular arrhythmias, treatment failures
including sudden cardiac death occur in a sizable percentage
of patients.
Predictors of outcome on amiodarone therapy. It is
still controversial whether noninducibility or change in the
mode of ventricular tachycardia induction can predict re-
currence (1,6, 14-17). Althoughwedid not finda correlation
between inducibility and outcome during amiodarone ther-
apy, only 14 (13%) of 108 patients in our group who had
inducible arrhythmiaat baseline study becamenoninducible,
and thus the number of patients in this group may have been
too small for analysis. Unfortunately, no other clinical or
electrophysiologic variable was associated with arrhythmia
recurrence in our population.
This study indicatesthat several variables were associated
with poorly tolerated arrhythmia recurrences during amio-
darone therapy. These variables included the hemodynamic
tolerance of the arrhythmia induced at electrophysiologic
testing during amiodarone therapy which had the highest
association (Fig. 2 and Table 3). Of note, 19 of the 22
patients witha poorly tolerated arrhythmia recurrence (Table
4) had a poorly tolerated arrhythmia induced in the electro-
physiology laboratory during amiodarone therapy (sensitiv-
ity 86%, specifi city 66%, positive predictive value 42% and
negative predictive value 95%). Horowitz et al. (18) re-
ported a similar correlation between symptoms during ar-
rhythmias induced at electrophysiologic testing during
amiodarone therapy and those at the time of recurrence.
Although often studied as a single group, patients pre-
senting with recurrent sustained ventricular tachycardia and
those presenting with cardiac arrest and ventricular fibril-
lation may represent separate populations with different ar-
rhythmia substrates (19,20) . We have found that patients
with ventricular fibrillation have a lower incidence of in-
ducible ventricular tachycardia or fibrillation at e1ectro-
physiologic testing than do those with recurrent ventricular
tachycardia (13). Stevenson et al. (19) reported that patients
with cardiac arrest were more likely to have two separate
areas of myocardial infarction than were those with sus-
tained hemodynamically tolerated ventricular tachycardia.
It therefore seems likely that some patients with recurrent
ventricular tachycardia constitute a group with a different
natural history from that of patients with ventricular fibril-
lation and cardiac arrest, and it is not surprising that tol-
erance of their recurrentarrhythmia during amiodarone ther-
apy might be dissimilar. It is also not surprising that the
ejection fraction may determine clinical outcome with re-
spect to arrhythmia tolerance. Patients who had a lower
ejection fraction may have been less able to tolerate an
arrhythmia of a given cycle length in similar situations and
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thus were more likely to have poorly tolerated arrhythmia
recurrences, In a patient with a given ejection fraction, the
presence of an aneurysm may actually signify better residual
ventricular function and thus may make a recurrent arrhyth-
mia better tolerated, The reason that patient age helped to
predict outcome cannot be easily explained. It is possible
that young age may be associated with a clinical factor more
likely to be associated with a poor prognosis but not assessed
in this study and not used in the multivariate analysis.
Clinical implications. Our results and prior experience
with amiodarone suggest that it is often, but not uniformly,
effective in the therapy of sustained ventricular arrhythmias.
Although a variety of factors, including the inducibility of
ventricular tachycardia (18), multivariate analysis of clinical
and electrophysiologic variables (21) and changes in ven-
tricular refractoriness and cycle length of induced ventric-
ular tachycardia at late electrophysiologic study (22) have
been shown to correlate with drug success in some studies,
the predictive accuracy of any of these factors has not been
uniformly established by all investigators. DiCarlo et al.
(21) identified a series of purely noninvasive variables that
appear to predict cardiac arrest or sudden death. The major
predictive variables in their analysis were history of cardiac
arrest or syncope and ejection fraction of <40%, variables
that we also found to have independent predictive value for
recurrent syncope or arrest. Because in that study and the
current one, sudden death occurred even in patients pre-
senting with ventricular tachycardia and a high ejection frac-
tion and because left ventricular dysfunction and cardiac
arrest are common in patients considered for amiodarone
therapy, there is a limit to the usefulness of these nonin-
vasive variables.
The information from these prior studies leaves unre-
solved the clinical question of whether empiric therapy with
a drug having < 100% efficacy is appropriate in patients
with a significant risk for sudden cardiac death, Our results
demonstrating that only 3 (5%) of the 57 patients who had
a well tolerated tachycardia induced during amiodarone ther-
apy had sudden death or syncope over a mean 27 month
follow-up period suggest an alternative approach. Electro-
physiologic testing using up to three extrastimuli and rapid
ventricular pacing may be employed to determine the tol-
erance of induced rhythm. In those patients in whom a
poorly tolerated tachycardia is induced, especially if other
associated variables such as low ejection fraction or a clin-
ical history of cardiac arrest are present, additional or al-
ternative modes of therapy such as surgery, implantable
cardioverter/defibrillator or additional antiarrhythmic drug
therapy might be considered.
Limitations of the current study. In evaluating the
tolerance of rhythms induced at electrophysiologic study,
we used an arbitrary definition of a hemodynamically stable
rhythm rather than a specific cycle length of induced ven-
tricular tachycardia because tolerance of tachycardia can
vary in different patients even when cycle lengths are similar
(Fig. I). In performing multivariate analysis we found that
"tolerated arrhythmias" as defined had a better correlation
with outcome rhythm than did tachycardia cycle length.
Nevertheless, determination of the hemodynamic stability
of arrhythmia induced at electrophysiologic study may oc-
casionally be difficult. Tachycardias with short cycle length
are often rapidly terminated by burst pacing to prevent de-
generation into ventricular fibrillation or other adverse con-
sequences. In addition, 22% of our patients were treated
with a type I antiarrhythmic agent during the follow-up
period. Although multivariate analysis did not show that the
use of type I agents was associated with outcome, the use
of these agents in our study group could introduce a potential
bias.
We acknowledge Linda Pentz and Faith Marie Hope for their secretarial
assistance in the preparation of this manuscript.
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